Clinical management and research on Multiple Myeloma, Chronic Myeloid Leukemia, Clinical management of Myelodysplastic Syndromes, Pediatric Acute Leukemias & Infections in Hematologic patients
To perform clinical research and clinical activities in the field of MGUS and Multiple Myeloma, to improve personal clinical skills and biological knowledge, to apply the most up to date diagnostic and therapeutic procedures, to finally ameliorate quality of medical care in the place I work, through foreign working experiences in international reference centers.
The Center for Cancer Biotherapy & Regenerative Medicine, Israel
Shimon Slavin, MD, Professor of Medicine, currently serving as the Medical & Scientific Director of Biotherapy International, an International Center for Cancer Immunotherapy & Regenerative Medicine in Tel Aviv, Israel. Slavin pioneered the use of immunotherapy mediated by allogeneic donor lymphocytes and innovative methods for stem cell transplantation for cure of hematological malignancies and solid tumors, and using hematopoietic stem cells for induction of transplantation tolerance to bone marrow and donor allografts. More recently, introducing the use of multi-potent mesenchymal stromal stem cells (MSC) for regenerative medicine for treatment of neurological, systemic and orthopedic disorders. Professor Slavin authors 4 books and >660 scientific publications and serves on many editorial boards of distinguished scientific and medical journals and a member on many national and international advisory boards. Slavin received many international awards in recognition of his excellence in basic science and clinical medicine based on his contributions towards large-scale clinical application of targeted, personalized medicine for treatment of cancer including hematologic malignancies, metastatic solid tumors and a long list of non-malignant disorders including cell-mediated regenerative and anti-aging medicine for a large number of indications, focusing on neuroinflammatory and neurodegenerative disorders and diabetes mellitus on the one hand and repair of cartilage in damaged joints on the other, using multi-potent MSCs that can be differentiated to cells resembling different tissues.